Ciprofloxacin

Generic Name: Ciprofloxacin

Brand Names: Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈FN_₃O_₃

CAS Number: 85721-33-1

Unique Ingredient Identifier: 5E8K9I0O4U

Background: Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.

The first ciprofloxacin containing product was FDA approved on 22 October 1987.

Indication: Ciprofloxacin is only indicated in infections caused by susceptible bacteria.
...

Associated Conditions: Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae

Associated Therapies: -

Clinical Trials

Pharmacokinetics of Ciprofloxacin in Pediatric Patients

Phase 4

Completed

Conditions: Urinary Tract Infection
Pyelonephritis

Interventions: Drug: ciprofloxacin

First Posted Date: 2015-11-05

Last Posted Date: 2023-09-05

Lead Sponsor: University Hospital, Ghent

Target Recruit Count: 22

Registration Number: NCT02598362

Locations: 🇧🇪
Universitair Ziekenhuis Brussel, Brussel, Belgium
🇧🇪
Ghent University Hospital, Ghent, Belgium

A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1

Withdrawn

Conditions: Lymphoma

Interventions: Drug: Belinostat
Drug: Rituximab
Drug: Cisplatin
Drug: Cytarabine
Drug: Dexamethasone
Drug: Ciprofloxacin
Drug: Fluconazole

First Posted Date: 2015-08-25

Last Posted Date: 2016-01-06

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT02532192

Antibiotic Treatment Trial for Small Intestinal Bacterial Overgrowth

Phase 4

Conditions: Small Intestinal Bacterial Overgrowth

Interventions: Drug: Placebo
Drug: Ciprofloxacin
Drug: Metronidazole

First Posted Date: 2015-06-01

Last Posted Date: 2015-06-01

Lead Sponsor: San Antonio Military Medical Center

Target Recruit Count: 180

Registration Number: NCT02458781

A Trial Assessing Peri-procedure Chemoprophylaxis During Transrectal Prostate Needle Biopsy

Phase 4

Completed

Conditions: Benign Prostate Hyperplasia

Interventions: Drug: ciprofloxacin and gentamycine
Drug: culture based chemoprophylaxis
Drug: ciprofloxacin

First Posted Date: 2015-04-22

Last Posted Date: 2017-04-04

Lead Sponsor: Mansoura University

Target Recruit Count: 510

Registration Number: NCT02423759

Locations: 🇪🇬
Urology and Nprhology Center, Mansoura, Aldakahlia, Egypt

Short-course Methenamine Hippurate for Prevention of Post-operative UTI

Not Applicable

Completed

Conditions: Catheter-Related Infections
Urinary Tract Infections

Interventions: Drug: methenamine hippurate
Drug: Ciprofloxacin

First Posted Date: 2015-02-09

Last Posted Date: 2022-02-25

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 201

Registration Number: NCT02358993

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
Pennsylvania Hospital, Philadelphia, Pennsylvania, United States

and more 1 locations

The Role of the Microbiota in the Systemic Immune Response

Not Applicable

Completed

Conditions: Healthy
Sepsis

Interventions: Drug: Vancomycin
Drug: Ciprofloxacin
Drug: Metronidazole

First Posted Date: 2015-01-16

Last Posted Date: 2015-01-16

Lead Sponsor: W.J. Wiersinga, MD, PhD

Target Recruit Count: 12

Registration Number: NCT02340182

Locations: 🇳🇱
Academisch Medisch Centrum, Amsterdam, Noord-Holland, Netherlands

Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis

Early Phase 1

Completed

Conditions: Alcoholic Hepatitis
Alcoholic Cirrhosis

Interventions: Drug: Ciprofloxacin
Drug: Placebo

First Posted Date: 2014-12-25

Last Posted Date: 2017-01-19

Lead Sponsor: University of Helsinki

Target Recruit Count: 22

Registration Number: NCT02326103

Locations: 🇫🇮
University Hospital of Helsinki, Helsinki, Finland

Targeted Retreatment of COPD Exacerbations

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Placebo
Drug: Ciprofloxacin

First Posted Date: 2014-11-24

Last Posted Date: 2021-03-08

Lead Sponsor: Imperial College London

Target Recruit Count: 144

Registration Number: NCT02300220

Locations: 🇬🇧
Aintree University Hospital NHS Foundation Trust, Liverpool, United Kingdom
🇬🇧
St Georges University Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧
Royal Brompton and Harefield Hospital NHS Foundation Trust, London, United Kingdom

and more 1 locations

Antibiotic Prophylaxis for Endoscopic Ultrasound Guided Fine Needle Aspiration of Pancreatic Cystic Lesions

Phase 4

Completed

Conditions: Pancreatic Cystic Lesion

Interventions: Drug: Placebo
Drug: Ciprofloxacin

First Posted Date: 2014-10-10

Last Posted Date: 2019-04-12

Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Target Recruit Count: 226

Registration Number: NCT02261896

Locations: 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: ciprofloxacin
Other: placebo
Other: quality-of-life assessment
Other: laboratory biomarker analysis

First Posted Date: 2014-09-30

Last Posted Date: 2018-07-05

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT02252978

Locations: 🇺🇸
Veterans Administration Medical Center., Salisbury, North Carolina, United States
🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy